Eledon Pharmaceuticals Shares Outstanding History (ELDN)
Eledon Pharmaceuticals reported 75.4M shares outstanding at the end of fiscal 2025.
View full Eledon Pharmaceuticals company overviewEledon Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 75.4M | 15.6M | +26.16% |
| 2024 | 2024-12-31 | 59.8M | 35.6M | +146.93% |
| 2023 | 2023-12-31 | 24.2M | 10.4M | +75.75% |
| 2022 | 2022-12-31 | 13.8M | −530,000 | −3.70% |
| 2021 | 2021-12-31 | 14.3M | −853,609 | −5.63% |
| 2020 | 2020-12-31 | 15.2M | 15.1M | +37779.22% |
| 2019 | 2019-12-31 | 40,022.987 | 10,941.833 | +37.63% |
| 2018 | 2018-12-31 | 29,081.154 | 26,642.703 | +1092.61% |
| 2017 | 2017-12-31 | 2,438.45 | 2,423.425 | +16129.47% |
| 2016 | 2016-12-31 | 15.025 | −80.648 | −84.30% |
| 2015 | 2015-12-31 | 95.672 | 0.909 | +0.96% |
| 2014 | 2014-12-31 | 94.763 | 92.674 | +4437.34% |
| 2013 | 2013-12-31 | 2.089 | — | — |
Eledon Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 80.9M | 21.0M | +35.09% |
| Q1 2026 | 2026-03-31 | 75.9M | 16.0M | +26.67% |
| Q4 2025 | 2025-12-31 | 75.4M | 15.6M | +26.16% |
| Q3 2025 | 2025-09-30 | 59.9M | 18.7M | +45.40% |
| Q2 2025 | 2025-06-30 | 59.9M | 21.4M | +55.51% |
| Q1 2025 | 2025-03-31 | 59.9M | 35.1M | +141.33% |
| Q4 2024 | 2024-12-31 | 59.8M | 35.6M | +146.93% |
| Q3 2024 | 2024-09-30 | 41.2M | 17.6M | +74.91% |
| Q2 2024 | 2024-06-30 | 38.5M | 15.5M | +67.10% |
| Q1 2024 | 2024-03-31 | 24.8M | 11.0M | +80.11% |
| Q4 2023 | 2023-12-31 | 24.2M | 10.4M | +75.75% |
| Q3 2023 | 2023-09-30 | 23.5M | 9.8M | +71.15% |
| Q2 2023 | 2023-06-30 | 23.0M | 9.3M | +67.51% |
| Q1 2023 | 2023-03-31 | 13.8M | 20,000 | +0.15% |
| Q4 2022 | 2022-12-31 | 13.8M | −530,000 | −3.70% |
| Q3 2022 | 2022-09-30 | 13.8M | 13.0M | +1630.79% |
| Q2 2022 | 2022-06-30 | 13.8M | 13.0M | +1630.81% |
| Q1 2022 | 2022-03-31 | 13.8M | 13.0M | +1630.81% |
| Q4 2021 | 2021-12-31 | 14.3M | 13.5M | +1598.64% |
| Q3 2021 | 2021-09-30 | 794,827.914 | 790,893.805 | +20103.50% |
| Q2 2021 | 2021-06-30 | 794,818.247 | 735,003.827 | +1228.81% |
| Q1 2021 | 2021-03-31 | 794,818.247 | 745,220.04 | +1502.51% |
| Q4 2020 | 2020-12-31 | 842,251.016 | 802,227.727 | +2004.40% |
| Q3 2020 | 2020-09-30 | 3,934.109 | −515.52 | −11.59% |
| Q2 2020 | 2020-06-30 | 59,814.42 | 55,364.791 | +1244.26% |
| Q1 2020 | 2020-03-31 | 49,598.207 | 46,358.323 | +1430.86% |
| Q4 2019 | 2019-12-31 | 40,023.289 | 36,792.052 | +1138.64% |
| Q3 2019 | 2019-09-30 | 4,449.629 | 4,090.603 | +1139.36% |
| Q2 2019 | 2019-06-30 | 4,449.629 | 4,091.179 | +1141.35% |
| Q1 2019 | 2019-03-31 | 3,239.884 | 2,881.435 | +803.86% |
| Q4 2018 | 2018-12-31 | 3,231.236 | 2,960.297 | +1092.61% |
| Q3 2018 | 2018-09-30 | 359.026 | 329.63 | +1121.35% |
| Q2 2018 | 2018-06-30 | 358.45 | 329.051 | +1119.26% |
| Q1 2018 | 2018-03-31 | 358.45 | 262.589 | +273.93% |
| Q4 2017 | 2017-12-31 | 270.939 | 175.078 | +182.64% |
| Q3 2017 | 2017-09-30 | 29.396 | −66.465 | −69.34% |
| Q2 2017 | 2017-06-30 | 29.399 | −66.433 | −69.32% |
| Q1 2017 | 2017-03-31 | 95.861 | 0.029 | +0.03% |
| Q4 2016 | 2016-12-31 | 95.861 | 0.188 | +0.20% |
| Q3 2016 | 2016-09-30 | 95.861 | 0.254 | +0.27% |
| Q2 2016 | 2016-06-30 | 95.832 | 0.626 | +0.66% |
| Q1 2016 | 2016-03-31 | 95.832 | 1.009 | +1.06% |
| Q4 2015 | 2015-12-31 | 95.672 | 0.909 | +0.96% |
| Q3 2015 | 2015-09-30 | 95.606 | 3.132 | +3.39% |
| Q2 2015 | 2015-06-30 | 95.206 | 93.117 | +4458.55% |
| Q1 2015 | 2015-03-31 | 94.823 | — | — |
| Q4 2014 | 2014-12-31 | 94.763 | — | — |
| Q3 2014 | 2014-09-30 | 92.474 | — | — |
| Q4 2013 | 2013-12-31 | 2.089 | — | — |
Eledon Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Eledon Pharmaceuticals's shares outstanding moved from 15.2M to 75.4M, a change of 60.3M. The latest reported quarter, Q2 2026, shows 80.9M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eledon Pharmaceuticals filings at SEC.gov ↗